BIOMARIN PHARMACEUTICAL INC's ticker is and the CUSIP is 09061GAH4. A total of 49 filers reported holding BIOMARIN PHARMACEUTICAL INC in Q3 2021. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,763,575 | -84.1% | 3,870,000 | -83.9% | 0.09% | -80.8% |
| Q2 2023 | $23,654,128 | -6.7% | 24,020,000 | -2.5% | 0.46% | -4.4% |
| Q1 2023 | $25,339,666 | +5.8% | 24,638,000 | +9.5% | 0.48% | +15.4% |
| Q4 2022 | $23,940,819 | -28.8% | 22,505,000 | -33.5% | 0.42% | -31.9% |
| Q3 2022 | $33,619,000 | -0.4% | 33,845,000 | -0.5% | 0.61% | +2.0% |
| Q2 2022 | $33,750,000 | -18.2% | 34,005,000 | -17.2% | 0.60% | -9.5% |
| Q1 2022 | $41,277,000 | -6.8% | 41,077,000 | -2.4% | 0.66% | -11.3% |
| Q4 2021 | $44,271,000 | -13.8% | 42,088,000 | -15.7% | 0.74% | -21.7% |
| Q3 2021 | $51,336,000 | -5.4% | 49,914,000 | -4.2% | 0.95% | -10.0% |
| Q2 2021 | $54,278,000 | -21.8% | 52,091,000 | -23.1% | 1.06% | -29.5% |
| Q1 2021 | $69,432,000 | -23.3% | 67,735,000 | -19.5% | 1.50% | -22.4% |
| Q4 2020 | $90,539,000 | +31.6% | 84,134,000 | +27.8% | 1.93% | +27.2% |
| Q3 2020 | $68,775,000 | +31.7% | 65,820,000 | +55.2% | 1.52% | +23.9% |
| Q2 2020 | $52,220,000 | -30.7% | 42,417,000 | -41.3% | 1.22% | -25.3% |
| Q1 2020 | $75,347,000 | -14.4% | 72,279,000 | -12.9% | 1.64% | -3.9% |
| Q4 2019 | $88,038,000 | +9.6% | 82,941,000 | +1.8% | 1.71% | +13.4% |
| Q3 2019 | $80,309,000 | +1.2% | 81,501,000 | +6.9% | 1.50% | -2.0% |
| Q2 2019 | $79,350,000 | +19.2% | 76,269,000 | +17.9% | 1.54% | +4.6% |
| Q1 2019 | $66,562,000 | +4.9% | 64,697,000 | +1.6% | 1.47% | -4.4% |
| Q4 2018 | $63,475,000 | -18.2% | 63,655,000 | -13.1% | 1.54% | -4.0% |
| Q3 2018 | $77,604,000 | +61.6% | 73,250,000 | +55.0% | 1.60% | +58.3% |
| Q2 2018 | $48,018,000 | +17.7% | 47,263,000 | +9.3% | 1.01% | +26.1% |
| Q1 2018 | $40,793,000 | +8.8% | 43,256,000 | +15.5% | 0.80% | +11.6% |
| Q4 2017 | $37,478,000 | +42.1% | 37,456,000 | +44.1% | 0.72% | +43.6% |
| Q3 2017 | $26,383,000 | – | 26,000,000 | – | 0.50% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SHENKMAN CAPITAL MANAGEMENT INC | 30,138,000 | $29,510,000 | 3.72% |
| PFM Health Sciences, LP | 45,910,000 | $46,002,000 | 1.72% |
| Cheyne Capital Management (UK) LLP | 2,320,000 | $2,330,000 | 1.47% |
| ADVENT CAPITAL MANAGEMENT /DE/ | 41,077,000 | $41,277,000 | 0.66% |
| SSI INVESTMENT MANAGEMENT LLC | 9,071,000 | $9,068,000 | 0.50% |
| PALISADE CAPITAL MANAGEMENT, LP | 14,548,000 | $14,612,000 | 0.34% |
| RWC Asset Management LLP | 7,500,000 | $7,552,000 | 0.21% |
| KBC Group NV | 400,000 | $40,316,000 | 0.15% |
| PROSPECTOR PARTNERS LLC | 1,000,000 | $1,000,000 | 0.12% |
| MACKAY SHIELDS LLC | 11,822,000 | $11,816,000 | 0.10% |